Mounjaro Becomes Top-Selling Drug as India's GLP-1 Market Hits ₹1,000 Crore

• India's GLP-1 drug market accelerated in November, surpassing ₹1,000 crore in value, driven by weight-loss prescriptions.
• Eli Lilly's Mounjaro leads the GLP-1 segment with an 86% market share, recording ₹108 crore in November sales and becoming India's top-selling brand.
• Novo Nordisk's Wegovy saw a significant volume increase in November (from 26,000 to 45,000 units) and market share rise (9% to 14%) after a 30-35% price cut.
• Regional GLP-1 sales surged, with Mumbai reporting a 297% year-on-year increase and Maharashtra contributing 24% of national sales in November.
• Novo Nordisk's oral GLP-1 drug Rybelsus recorded ₹27 crore in November sales, but its uptake has slowed compared to injectable therapies.

Why It Matters: GLP-1 drugs are rapidly changing India's pharmaceutical landscape.